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Spectrum of mutational signatures 
in T‑cell lymphoma reveals a key 
role for UV radiation in cutaneous 
T‑cell lymphoma
Christine L. Jones1, Andrea Degasperi2,3, Vieri Grandi1, Tauanne D. Amarante2,3, 
Genomics England Research Consortium*, Tracey J. Mitchell1, Serena Nik‑Zainal2,3 & 
Sean J. Whittaker1*
T‑cell non‑Hodgkin’s lymphomas develop following transformation of tissue resident T‑cells. We 
performed a meta‑analysis of whole exome sequencing data from 403 patients with eight subtypes 
of T‑cell non‑Hodgkin’s lymphoma to identify mutational signatures and associated recurrent 
gene mutations. Signature 1, indicative of age‑related deamination, was prevalent across all T‑cell 
lymphomas, reflecting the derivation of these malignancies from memory T‑cells. Adult T‑cell 
leukemia‑lymphoma was specifically associated with signature 17, which was found to correlate 
with the IRF4 K59R mutation that is exclusive to Adult T‑cell leukemia‑lymphoma. Signature 7, 
implicating UV exposure was uniquely identified in cutaneous T‑cell lymphoma (CTCL), contributing 
52% of the mutational burden in mycosis fungoides and 23% in Sezary syndrome. Importantly this 
UV signature was observed in CD4 + T‑cells isolated from the blood of Sezary syndrome patients 
suggesting extensive re‑circulation of these T‑cells through skin and blood. Analysis of non‑Hodgkin’s 
T‑cell lymphoma cases submitted to the national 100,000 WGS project confirmed that signature 7 
was only identified in CTCL strongly implicating UV radiation in the pathogenesis of cutaneous T‑cell 
lymphoma.
Non-Hodgkin’s lymphomas (NHL) consist of distinct clinico-pathologic and molecular entities arising from 
nodal or extra-nodal  sites1. T-cell lymphomas often develop in extra-nodal sites, constitute only 10–15% of NHL 
in the west, although higher rates of 20–25% are reported in Asia, and arise from tissue resident αβ or γδ T-cells2. 
Whilst the incidence of NHL has increased, the underlying aetiology remains poorly understood.
Recurrent chromosomal translocations are common in B-cell NHL and are due to intrinsic molecular mecha-
nisms including aberrant V(D)J recombination in which different genes are juxtaposed with immunoglobulin 
promotors, somatic hypermutation and class switch  recombination3. For mature T-cell NHL, the prevalence 
of recurrent translocations is less, with notable exceptions such as the t(2;5) in ALK + anaplastic large cell 
 lymphomas4, reflecting the lack of somatic hypermutation and class switch recombination in healthy mature 
T-cells. In contrast the identification of extrinsic factors has proved elusive, with the exception of viral transfor-
mation such as Adult T-cell leukemia-lymphoma (ATLL) associated with HTLV-15 and EBV associated  NHL6.
A combination of intrinsic and extrinsic mutational processes cause a characteristic mutational spectrum. 
Consequently when a cell is clonally expanded through malignancy, these patterns can be detected within the 
tumour. The patterns of mutation are defined by assessing the six substitution types which can occur (C>A, C>G, 
C>T, T>A, T>C, and T>G) and considering the 5′ and 3′ nucleotide context giving 96 different trinucleotide 
mutation  types7. An analysis of over 10,000 exomes and 1000 genomes across 40 types of cancer in The Cancer 
Genome Atlas (TCGA) identified 30 distinct signatures, some of which can be attributed to known mutagens 
(COSMIC mutational signatures v2, available at https ://cance r.sange r.ac.uk/cosmi c/signa tures _v2).
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Previous studies showed that mutational signatures in B-cell NHL including B-CLL are often associated with 
intrinsic abnormalities such as the COSMIC signature 9 due to somatic hypermutation associated with aberrant 
activation induced cytosine  deaminase8. Furthermore, single cell whole genome sequencing studies of B-cells 
from healthy volunteers suggests that mutational signatures correlate with intrinsic factors including the age 
associated COSMIC signature 1 due to spontaneous deamination of methylated cytosines as well as COSMIC 
signature  99. As T-cell lymphomas are not included in TCGA, there have been no comprehensive studies of 
mutational signatures in T-cell NHL although recent high-throughput sequencing studies have identified putative 
driver gene mutations targeting specific signalling pathways notably TCR, NF-kB and JAK-STAT  signalling10–14. 
These findings suggest that some T-cell NHL are dependent on TCR signalling analogous to a dependence on 
BCR signalling in B-cell  NHL15.
In order to identify causal factors in T-cell NHL, we performed a systematic review of the literature and identi-
fied 14 published WES studies of T-cell NHLs from which mutational data could be  combined11–14,16–25. Using this 
dataset of over 400 whole exome sequences we deconvoluted the mutational signatures present in eight different 
subtypes of mature T-cell lymphomas. Whilst this analysis indicates that all mature T-cell NHLs have age related 
signatures, distinct signatures are present, including signature 17 associated with HTLV-1 transformed ATLL and 
UV signature 7 in cutaneous T-cell lymphoma (CTCL). We show that this clonotypic UV signature is present in 
leukemic T-cells, presumably due to recirculation from skin. These findings have important implications for the 
pathogenesis of CTCL and suggest that skin resident memory T-cells are susceptible to the mutagenic as well as 
the immunomodulatory effects of UV.
Results
T‑cell lymphomas have a variable mutational load. Since mature T-cell NHLs have not been included 
in any of the large pan-cancer sequencing projects, we performed a comprehensive review of the literature. 34 
studies were identified which included whole exome data from 631 patients. Overall 14 studies comprising 403 
patients met our eligibility criteria (Table 1).
There was a striking disparity in the number of exomes sequenced between the subtypes, particularly when 
compared to the relative incidence of each subtype (Fig. 1). Notably, rare subtypes such as Sezary syndrome (SS) 
and ATLL account for 45% of the exomes sequenced whilst only representing 4% of mature T-cell NHL cases in 
the  US26. On the other hand, mycosis fungoides (MF) and peripheral T-cell lymphoma (PTCL) account for only 
5% of the exomes sequenced whilst representing 45% of mature T-cell NHL cases. This is likely because both 
SS and ATLL are leukaemic variants facilitating isolation of clonal populations of tumour cells from peripheral 
blood.
Examining the distribution of mutational burden within and between subtypes of T-cell lymphoma revealed 
that SS has both the highest median number of coding SNVs per sample and the widest range (Fig. 2), support-
ing previous observations of heterogeneity in  SS10. ATLL, which is driven by HTLV-1, has a high mutation rate 
with a much narrower distribution. Enteropathy-associated T-cell lymphoma (EATL) and hepatosplenic T-cell 
lymphoma (HSTL), which often arise from γδ T-cells, have the lowest mutation rate, although it is notable that 
the EATL samples have a bimodal distribution. This split corresponds to the study from Roberti et al.20 averaging 
77 SNVs and Moffitt et al.14 averaging 2.5 per sample. The one sample from Palomero et al.18 sits with the higher 
group at 42 suggesting that the filtering criteria used by Moffitt et. al. may have been more stringent. This high-
lights that, because our analysis was based on published data from multiple sources, differences in sequencing 
depth and filtering strategy could contribute to variability in results for other subtypes as well. However, samples 
from multiple SS studies were analysed and showed comparable mutational burden suggesting that technical 
differences did not contribute significantly to variation in SS results.
Table 1.  Details of the studies included and the number of samples with each disease subtype.
AITL ATLL EATL HSTL MF NKTCL PTCL SS
Choi  201516 – – – – – – – 33 33
da Silva Almeida  201517 – – – – 8 – – 26 34
Jiang  201512 – – – – – 25 – – 25
Kataoka  201511 – 81 – – – – – – 81
McKinney  201713 – – – 64 – – – – 64
Moffitt  201714 – – 58 – – – – – 58
Palomero  201418 3 – 1 – – 2 6 – 12
Prasad  201619 – – – – – – – 12 12
Roberti  201620 – – 15 – – – – – 15
Sakata–Yanagimoto  201421 3 – – – – – 3 – 6
Ungewickell  201522 – – – – 6 – – 5 11
Wang  201523 – – – – – – – 37 37
Woollard  201624 – – – – – – – 10 10
Yoo  201425 5 – – – – – – – 5
11 81 74 64 14 27 9 123
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Figure 1.  Comparison of the distribution of number of exomes sequenced with the US incidence rate of each 
subtype. Literature analysis identified 631 whole exome sequences performed on mature T-cell NHL samples. 
US Incidence rates are derived from the 2016 US lymphoid malignancy  statistics26 which estimated 8,380 new 



































Figure 2.  Number of coding SNVs per sample across disease subtypes. Data were collated for those studies 
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Recurrent driver mutations across T‑cell NHL subtypes. Recurrent mutations in the driver genes, 
as defined by Park et. al.10 were assessed in three or more patients within the cohort and their distribution 
compared across disease subtypes (Fig. 3). Overall 34 recurrent mutations were identified in 20 genes across dif-
ferent T-cell lymphoma subtypes. EATL, HSTL, Angioimmunoblastic T-cell lymphoma (AITL) and ATLL each 
have at least one highly recurrent mutation, while the other subtypes show a more heterogeneous pattern. 31 of 
the 34 recurrent mutations are listed in the COSMIC catalogue, of which 90% are associated with haematologic 
 malignancies27. In addition, functional characterisation has predominately shown gain of function mutations 
leading to increased TCR signalling and proliferation. Key exceptions are RHOA G17V, a loss of function muta-
tion leading to dominant negative inhibition of wild type RHOA GTPase  activity18,21 and TP53 R196* a trunca-
tion which lacks tumour suppressor activity and is observed in a wide range of solid  tumours28.
Recurrent JAK mutations were mostly restricted to EATL whilst recurrent STAT mutations were prevalent in 
both EATL and HSTL. Since EATL and HSTL frequently involve γδ T-cells, we checked whether the recurrent 
JAK/STAT mutations were restricted to T-cell lymphomas derived from γδ as opposed to αβ T-cells. However no 
association was found suggesting that the restriction of certain recurrent mutations to particular disease subtypes 
reflects the tissue specificity of those T-cells rather than the TCR type. Several recurrent mutations involved dif-
ferent nucleotide changes resulting in the same amino acid change. For example JAK3 M511I was caused by a 
C>A substitution in 3 patients and a C>G substitution in 3 patients indicating a selection pressure for the same 
amino acid change even though it may be generated through different mutational processes.
Landscape of Mutational Signatures in T‑cell NHL. The full list of exome SNVs were grouped by 
disease subtype and subject to signature fitting against the 30 COSMIC signatures. This revealed contributions 
from nine signatures across all the subtypes with signature 1, the age-related deamination of 5-methylcytosine, 
being the most prevalent (Fig. 4a). Comparison between the original mutational catalogues and reconstructed 
profiles based on the extracted signature contributions suggested that no further undefined signatures were 
involved. A lower cosine similarity was observed between original and reconstructed plots for PTCL and HSTL 
but this probably reflects a lower total number of SNVs compared to the other subtypes. In the context of exome 
sequencing data, signatures such as 3, 5, and 8 are challenging to assign due to their relatively flat and featureless 
SNV pattern and may well be false  positives29. Hence, we focussed on signatures with a distinctive profile and 
potential functional relevance.
Cutaneous T-cell lymphomas, MF and SS, showed a strong contribution from signature 7 (Fig. 4b) indicat-
ing a potential causal link with UV exposure. Data were also examined on a study specific level and all eight 
studies of CTCL patients demonstrated presence of the UV signature contributing between 10.8 and 57.6% 
of the mutational burden. Crucially, all the SS samples were obtained from peripheral blood with a dominant 
clonal T-cell population and 41% of patients were treatment naïve at the time of sampling. This suggests that the 
leukaemic T-cells in SS must have been circulating within the skin for a prolonged period prior to initiation of 
clonal expansion in order to accumulate a large number of UV mutations.
To establish whether all SS patients showed a contribution from signature 7, we analysed exome SNVs from 
individual SS patients. Of the 90 SS patients with sufficient mutations to define signatures, 67 (74%) had a sig-
nature 7 contribution representing between 7.5 and 88% of the overall SNV catalogue (Supplementary Table 1). 
However there was no correlation between the percentage contribution of signature 7 and mutational burden 
in SS patients. Overall 41% of SS patients were treatment naïve at the time of analysis and, where it was possible 
to identify treatment of individual patients, 78% of treatment naïve patients showed a signature 7 contribution. 

















































































































































































































































































































































































































































































Figure 3.  Recurrent driver gene mutations in mature T-cell NHL. Heatmap showing the number of patients 
with a given driver gene mutation for each subtype where a given variant occurred in three or more patients.
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PUVA), however this information was provided in summary form and so it was not possible to allocate treat-
ments to samples from specific individuals.
To validate this finding we examined data generated by the UK 100,000 genomes project. Six newly diag-
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Figure 4.  Mutational signatures identified in T-cell lymphoma. (a) matrix showing the percentage of mutations 
in each disease subtype assigned to the 30 COSMIC signatures. (b) plots showing the likelihood of each 
mutation in each trinucleotide context for Signatures 1 and 7 as per COSMIC mutational signatures v2 and the 
observed SNV catalogues for Sezary syndrome and mycosis fungoides.
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of 3–8.4 somatic coding variants per Mb to which signature 7 contributed between 25 and 61%. Two cases of 
systemic nodal T-cell lymphoma were also sequenced revealing mutational burdens of 0.3 and 3.5 somatic coding 
variants per Mb with neither showing any contribution from signature 7. Notably, significant bias towards the 
untranscribed strand was seen for C>T mutations in cutaneous but not nodal T-cell lymphomas with frequent 
double nucleotide substitutions CC>TT (Fig. 5) both of which are characteristic features of UV induced mutation.
A significant contribution was noted in ATLL from signature 17. Although the aetiology of signature 17 is 
unknown, this signature is associated with a high mutational load and neoantigen burden subtype of oesopho-
geal  adenocarcinoma30 and is enriched in metastatic tissue of colorectal  cancer31. ATLL patients have a variable 
course consisting of indolent (smouldering and chronic) and aggressive (lymphoma and acute) subtypes. Hence, 
we examined whether there was an association between aggressive subtypes and signature 17. Only 1/13 (8%) 
indolent ATLL exhibited signature 17, whilst 9/32 (28%) aggressive ATLL exhibited signature 17 but this differ-
ence did not reach significance in a Fisher’s exact test.
Significant associations between mutational signatures and driver mutations. We used the 
method of Temko et. al.32 to assess the potential causative role of mutational signatures in relation to recurrent 
driver gene mutations. Causal peaks were used to estimate the contribution of each signature and compared 
between wild type and mutant groups for each recurrent driver gene mutation which occurred in five or more 
patients. Using the Bonferroni corrected p-value of 0.00029, two significant associations were observed, between 
STAT3 Y640F and signature 5 (Fig. 6) and between IRF4 K59R and signature 17 (Fig. 7). Whilst the STAT3 
Y640F mutation was distributed across T-cell NHL cases, specifically 7 ATLL, 1 NK/T-cell lymphoma (NKTCL) 
and 1 MF, the IRF4 K59R mutation was only seen in ATLL patients, consistent with the restriction of signature 
17 to these patients. For both of these associations the underlying nucleotide change was most likely to have been 
generated by the signature observed. No further associations were identified by examining the data on a disease 
subtype level.
Due to the dominant contributions of C>T peaks in signatures 1, 7 and 30, the only context in which we could 
clearly define a causal association for signature 7 was for C>T in a TCC context. Of the recurrent driver muta-
tions, only PLCG1 S345F occurs in this context and there was no significant association between this recurrent 
mutation and signature 7. Additionally this mutation was not restricted to cutaneous lymphoma, being observed 
in 3 SS, 3 ATLL and 1 AITL patients suggesting it originated from another mutational process. This method of 
analysis has a much greater power over the whole cohort and within individual disease subtypes with highly 
recurrent mutations, and so the lack of significant association of specific gene variants with signature 7 causal 
peaks likely reflects the absence of highly recurrent mutations in CTCL.
UV mutational signatures in healthy T‑cells. If the presence of the UV signature in CTCL reflects 
prior exposure of the originating T-cell to UV whilst circulating in the skin, we might expect a proportion of 
healthy peripheral blood memory T-cells to show similar UV induced mutations. In the absence of a clonal pro-
liferation, this can only be identified by looking at the mutational spectrum of single cells. No single cell whole 
genome or exome sequencing has been performed on healthy T-cells but we did identify a dataset of RNA-seq 
from CD4 + T-cells where the full length transcript has been sequenced which allows mutation  calling33. We 
analysed three subjects where both  TEM and  TCM single cells had been sequenced. Data processing and mutation 
calling were performed as described in the supplementary materials. No clear UV signature was observed in 94 
cells from Donor 3, 91 cells from Donor 6 or 90 cells from Donor 12, and in each donor a similar mutational 
burden was observed between  TEM and  TCM cells. It is estimated that almost twice as many T-cells are perma-
nently resident in the skin than circulating in the  blood34 but the proportion of T-cells which freely re-circulate 
through skin and blood is not well characterised. Hence we may need to analyse a much greater number of cells 
to observe those exposed to UV.
Discussion
There are several findings in this study which provide insight into the pathogenesis of mature T-cell NHL and 
have immunobiologic and therapeutic relevance. Strikingly cutaneous T-cell lymphomas, specifically SS and 
MF variants, show an obvious clonotypic UV signature 7 associated with a high tumour mutational burden 
as expected for malignancies linked to a specific mutagen. This UV signature contributed 23% and 52% of the 
mutational load for the SS and MF cohorts respectively. Specifically the UV signature was identified in peripheral 
blood T-cells from 74% (67/90) of SS patients representing between 7.5 and 88% of the overall SNV mutational 
burden. Not surprisingly signature 1, associated with age related deamination of methylated cytosines, was 
detected in all T-cell NHL with the exception of MF in which signature 1 is likely masked by the large contribu-
tion of the UV signature. Two mutational signatures were associated with the HTLV-1 associated ATLL cohort 
namely signature 1, and signature 17 which is of unknown cause but associated with gastric  cancer35 and oesopha-
geal  adenocarcinoma30. Our computational power to deconvolute mutational signatures reflects the total number 
of tumours compared to the mutational  load36 and therefore the smaller sample size and low mutational burden 
of the other T-cell NHL cohorts limits an accurate interpretation. Future whole genome studies, particularly of 
non-cutaneous T-cell NHL subtypes, could yield additional insight into mutational processes as greater coverage 
would allow increased power for signature extraction.
MF is derived from skin resident effector memory T-cells and, although previous studies suggested that leu-
kaemic T-cells from SS patients were derived from central memory T-cells37, the presence of a UV signature in 
DNA derived from peripheral blood CD4 + T-cells of SS patients supports data that  TCM exhibit marked plasticity 
contributing to circulation from skin through peripheral  blood38. Indeed, studies have shown that low dose solar 
simulated irradiation of whole skin causes alterations of gene expression in peripheral blood derived T-cells39 
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Figure 5.  Characteristic features of UV induced mutation are observed only in patients with cutaneous T-cell lymphoma. 
Whole genome sequencing data from the UK 100,000 genomes project comparing representative cutaneous and nodal 
T-cell lymphoma patients. The highlighted track on the circos plots is a rainfall diagram of SNVs where distance from the 
centre is proportional to the logarithm of the distance between adjacent SNVs. Cutaneous T-cell lymphoma patients have 
a characteristic inner ring of C>T variants due to CC>TT substitutions, which are also clear in the light green bar on the 
dinucleotide variants plot. Single nucleotide variants occurring within gene bodies were assessed to determine whether they 
affect the transcriptional or non-transcriptional strand. Significant transcriptional strand bias was observed for C>T mutations 
in cutaneous T-cell lymphoma but not nodal T-cell lymphoma indicating transcription-coupled nucleotide excision repair, a 
feature of UV induced mutation.
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suggesting that UVR may have a direct effect on the blood transcriptome of T-cells circulating through the skin. 
Our previous study of MF suggested that p53 gene mutations were characteristic of UV  damage40 and several 
whole exome/genome datasets including our own have suggested a possible UV  influence23,24,41. Importantly, 
exposure of cultured cells to simulated solar radiation followed by sequencing of clones generates a mutational 
profile which replicates that of signature  742 providing molecular evidence for the link between UV and signa-
ture 7. Combining data from multiple whole exome T-cell NHL studies has allowed us to confirm that this UV 
signature is associated with and restricted to CTCL.
Overall 41% of SS patients were treatment naïve and a UV signature was detected in a high proportion of these 
patients. Other patients received various treatments including photopheresis, in which an enriched population 
Figure 6.  Patients with the STAT3 Y640F mutation showed significantly greater contribution of signature 5 
to their mutational catalogue. Wilcoxon rank sum test was used to compare the contribution of each signature 
between the groups mutant or WT for a given mutation.
Figure 7.  Patients with the IRF4 K59R mutation showed significantly greater contribution of signature 17 to 
their mutational catalogue. Wilcoxon rank sum test was used to compare the contribution of each signature 
between the groups mutant or WT for a given mutation.
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of white blood cells is exposed to psoralens and UVA extra-corporeally and reinfused, and PUVA phototherapy 
consisting of oral psoralens and UVA irradiation of skin. However the mutational signatures detected are based 
on the analysis of of clonotypic causal peaks. Therefore critically our findings reflect the impact of environmental 
UV on the original skin resident T-cell prior to clonal expansion rather than subclonal evolution of the malignant 
T-cell as subsequent UV induced mutations would not be present in all tumour cells and therefore would not 
be detectable as a clonotypic signature. Furthermore PUVA phototherapy and photopheresis are characterised 
mostly by UVA induced cross linking of DNA by psoralens to produce pyrimidine mutations in a TpA sequence 
context. Until recently mutational signatures have been based on single base substitutions, but analysis of large 
whole genome cancer datasets has now expanded the number of distinct signatures after identification of those 
associated with double base substitutions and  indels43. Specifically this study has decomposed the UV signature 
into four constituent types with two consisting of C>T at TCN and C>T at CCN, whilst the other two consist 
of T>A at NTT and T>C at NTT sites. In fact our analysis of T-cell NHL cases submitted to the UK national 
100,000 WGS project has confirmed a high frequency of CC>TT double substitutions at diprimidine sites with 
very high mutational burdens confined only to untreated CTCL cases. In addition there was a significant bias 
towards C>T mutations in the unstranscribed strand in the CTCL cases.
Epidemiological case–control studies have suggested that occupational solar UV exposure is a risk factor for 
NHL in Caucasian  populations44 however most of the studies in this meta-analysis analysed NHL as a cohort 
and did not divide according to specific lymphoma subtypes. One European case–control study observed a link 
between MF and occupational sun  exposure45. In contrast population based registry data from Australia sug-
gested that the incidence of NHL, including cutaneous lymphomas, shows an inverse relationship to latitude, 
suggesting that UV is protective possibly due to immuno-modulatory effects of  UV46. A study using US SEER 
data found no overall trend between UV radiation and cutaneous lymphoma risk but did observe that ethnic-
ity significantly modified the association of UVR and  risk47. This complex picture highlights the challenge of 
unravelling the role of UV in NHL. Our data provide molecular evidence for a role of UV in the development of 
cutaneous T-cell lymphoma only, highlighting the need to examine epidemiological data on a subtype specific 
basis. Assessment of UV exposure is also challenging with larger population based studies relying on location 
based estimation whilst personal exposure estimation based on questionnaires increases accuracy but limits 
the study size.
UV radiation is known to have an immune modulatory effect on the skin by inducing a  Treg  response48. What 
has not been clear is the mutational impact of UV upon skin-resident T-cells. In contrast to other rapidly divid-
ing cells, studies have shown that irradiation of memory CD8 + T-cells ex vivo rapidly induces all DNA damage 
response pathways and cell cycle checkpoints during the secondary expansion phase and in the absence of repair, 
CD8 + T-cells are driven to compulsive suicide to prevent  transformation49. DNA damage repair pathways may 
therefore play a critical role in preventing UV induced transformation of skin-resident T-cells. Indeed, het-
erozygote p53+/− mice develop B-cell lymphomas after UV  irradiation50. Functional studies are now required 
to investigate the role of UV in the pathogenesis of T-cell lymphomas.
We identified 20 genes harbouring 34 recurrent variants across different subtypes of T-cell lymphoma, the 
majority of which are restricted to malignancies of haematopoietic and lymphoid origin and influence T-cell 
signalling pathways. Our statistical analysis of putative driver gene mutations and specific causal peaks within 
each signature revealed several associations. The recurrent STAT3 Y640F mutation is found in different T-cell 
NHL including both CTCL and ATLL and confers constitutive STAT3 phosphorylation and increased transcrip-
tional  activity51. The association of the STAT3 Y604F variant with signature 5 is not surprising as this signature 
is considered to be a feature of  ageing52. We were unable to assess the signature association of recurrent STAT5B 
N642H, detected almost exclusively in EATL/HSTL. This is due to the low mutational load in these subtypes 
which prevented the assignment of signature contributions on an individual basis. Whole genome sequencing 
of these subtypes would provide a clearer picture of the mutational processes involved.
The recurrent IRF4 K59R mutation in ATLL was associated with signature 17 unique to ATLL. Mutations of 
IRF4 are frequent in B-cell malignancies including  myeloma53,  DLBCL54 and primary mediastinal large B-cell 
 lymphoma55 and IRF4 gene rearrangements are also found in  myeloma56 and  PTCL57, but intriguingly the 
most common point mutation, the K59R variant, is exclusively associated with  ATLL58. The HTLV-1 Tax gene 
induces activation of the NF-kB pathway in ATLL and subsequent induction of IRF4, a key transcription factor 
downstream of NF-kB59. Tax gene expression is subsequently  downregulated60 and transformed T-cells in ATLL 
accumulate activating mutations of genes involved in TCR, NF-kB, and CD28 signalling pathways including the 
IRF4 K59R  mutant11. Functional studies have confirmed that the activating K59R mutation is a key driver in 
ATLL and its effects include repression of apoptosis and DNA  repair58. Specifically constitutive expression of IRF4 
in T-cells directly reduces expression of critical DNA repair and checkpoint genes and increases the sensitivity 
of T-cells to genotoxic  stress61. Therefore the association of causal signature 17 peaks with the IRF4 K59R muta-
tion in ATLL suggests a strong selection pressure for this mutation which could directly generate an increased 
mutation rate of other genes due to suppression of DNA repair mechanisms. The underlying cause for signature 
17 remains unknown although increasing evidence suggests oxidative damage may  contribute62. The role of IRF4 
in repression of DNA repair mechanisms provides further insight into the aetiology of signature 17 in ATLL.
In conclusion the identification of a clonotypic UV mutational signature in MF and CD4 + peripheral blood 
T-cells from SS patients confirms that environmental UV exposure contributes to the mutational burden and 
is a likely causal factor in the transformation of T-cells which are either circulating through or resident in the 
skin. Importantly these findings also raise the possibility that non-malignant T-cells could acquire UV induced 
mutations which might modulate normal immune responses.
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Methods
Data assembly and pre‑processing. On  1st June 2017 Pubmed was searched using the terms ("Next 
Generation Sequencing"[All Fields] OR "Whole Exome Sequencing"[All Fields]) AND ("T cell lymphoma"[Tiab] 
OR "Mycosis Fungoides"[Tiab] OR "Sezary Syndrome"[Tiab] OR "T cell prolymphocytic leukaemia"[Tiab] OR 
"T cell large granular lymphocyte leukaemia"[Tiab] OR "Adult T cell leukemia/lymphoma"[Tiab] OR "CD30 
positive T cell lymphoproliferative disorder"[Tiab]) NOT ("review"[Publication Type]) and Scopus was searched 
using the terms ((ALL ("Next Generation Sequencing") OR ALL ("Whole Exome Sequencing")) AND (TITLE-
ABS-KEY ("T cell lymphoma") OR TITLE-ABS-KEY ("Mycosis Fungoides") OR TITLE-ABS-KEY ("Sezary Syn-
drome") OR TITLE-ABS-KEY ("T cell prolymphocytic leukaemia") OR TITLE-ABS-KEY ("T cell large granu-
lar lymphocyte leukaemia") OR TITLE-ABS-KEY ("Adult T cell leukemia/lymphoma") OR TITLE-ABS-KEY 
("CD30 positive T cell lymphoproliferative disorder"))) AND (LIMIT-TO (DOCTYPE , "ar") OR LIMIT-TO 
(DOCTYPE , "le")). The outputs were combined to identify 121 unique reports which were manually curated to 
identify those which reported whole exome sequencing. Searches were also performed of sequencing archives 
including NCBI Sequence Read Archive, NCBI dbGap, EMBL European Genome-phenome Archive and EMBL 
European Nucleotide Archive to check for data which was not covered by the literature search.
To avoid skewing the analysis, we included only studies where full mutation details were included in the 
published data and studies were excluded if they only listed driver mutations, or genes which were mutated in 
more than one patient. We also only included samples where mutation calling was performed by comparison 
to a paired germline control.
Choi et. al. only included a list of mutations in potential driver genes so their full mutation list was extracted 
from a data resource covering all the sequencing of  CTCL63. Mutations from whole exome data of 403 patients 
were included and a summary by study and disease subtype is provided in Table 1. Experimental details, includ-
ing capture and variant calling methods, of each study are included in Supplementary Table 2.
Mutation lists were extracted from the supplementary tables of studies and combined in  R64. Where the refer-
ence assembly was not hg19, co-ordinates were lifted over using the  rtracklayer65 package. Finally, co-ordinates 
were sense checked using the  GenomicRanges66 and BSgenome.Hsapiens.UCSC.hg1967 packages to ensure that 
the listed reference base corresponded to the given location. The full mutation dataset generated and analysed 
during the study are available in the Dryad repository, https ://doi.org/10.5061/dryad .8cz8w 9gkm.
Clinical data, including age, sex, disease stage and treatment regime at sampling or prior to sample collection, 
were collected from each publication where provided but this information was incomplete and resultant clinical 
groupings were too small for subgroup analyses. Treatment data was available for 50% of the cohort of which 
70% were treatment naïve at the time of sampling (Supplementary Table 3).
Identification of mutational signatures. Combined SNV catalogues, i.e. the count of each mutation 
type (e.g. C>T) in different trinucleotide contexts (e.g. A[C>T]A), were calculated for each disease subtype and 
mutational signatures identified using a non-negative least squares fit against the set of 30 COSMIC signatures 
adjusted for exome trinucleotide frequencies. As exome data is prone to false positives, a post processing algo-
rithm was applied to each subtype to remove signatures which had a minimal impact upon the cosine similar-
ity between the SNV catalogue and that reconstructed using the identified signature contributions (maximum 
allowed reduction in cosine similarity was 0.05).
For identification of signatures on an individual patient level, fitting was restricted to the subset of signatures 
identified on the disease  level29. Additionally, signatures were removed if assigned to less than 20 mutations in a 
sample and no signatures were assigned if the cosine similarity between the model and the data was less than 0.6.
Association between recurrent mutations and signatures. A study by Park et.  al10 defined 55 driver 
genes in CTCL using multiple independent analytical pipelines and confirmed their relevance to the wider 
subset of mature T-cell NHL and so were used in this analysis. SNV catalogues were limited to those specific 
variants which recurred within these 55 defined driver genes. 34 recurrent variants were identified in three or 
more patients, however we determined that recurrence in at least five patients was required to identify signature 
associations as otherwise the power of the statistical test was decreased. A separate analysis of each tumour type 
was performed but this approach was limited with the exception of ATLL because of the requirement for both 
a highly recurrent variant and sufficient SNVs per patient to estimate a signature contribution. Causal peaks for 
each signature were assigned by comparing the profiles of the nine signatures and identifying mutation contexts 
strongly associated with a particular signature. Summation of the causal peaks for each signature was then used 
to calculate a percentage contribution of that signature in all patients with more than 20 SNVs. For each recur-
rent mutation and signature pair, a Wilcoxon rank sum test was used to determine if there was a significant dif-
ference in signature contribution between the wild type and mutant groups.
Validation in UK 100,000 genomes cohort. All samples were processed by Genomics England and 
analysed through their cancer pipeline. Briefly, samples were prepared using an Illumina TruSeq DNA PCR-Free 
preparation kit and then sequenced on a HiSeq X generating 150 bp paired-end reads. Quantity and quality of 
sequence and presence of cross-contamination were assessed for each sample prior to variant calling. Reads 
were aligned to human reference genome GRCh38-Decoy + EBV by ISAAC then Strelka was used to call small 
variants and perform tumour-normal subtraction. Gene annotations were used to determine whether mutations 
within genes affected the transcriptional or non-transcriptional strand.
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